ANIKA THERAPEUTICS, INC. Toevoegen aan een lijst
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 26,49 USD | +2,32% |
|
+2,28% | +16,90% |
| 14/03 | ANIKA THERAPEUTICS, INC. : Barrington Research herhaalt koopadvies | ZM |
| 13/03 | Transcript : Anika Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 |
Totale waarde
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Marktkapitalisatie 1 | 739,9 | 643,3 | 517,3 | 432,4 | 331,8 | 388,4 | - | - |
| Bedrijfswaarde 1 | 739,9 | 643,3 | 422,9 | 432,4 | 331,8 | 304,4 | 388,4 | 388,4 |
| K/w-verhouding | 27,4 x | -26,8 x | 128 x | -29 x | -4,02 x | -173 x | 64,1 x | 70,6 x |
| Dividendrendement | - | - | - | - | - | - | - | - |
| Marktkapitalisatie/omzet | 6,46 x | 4,93 x | 3,5 x | 2,77 x | 1,99 x | 2,28 x | 2,14 x | 2 x |
| Bedrijfswaarde/omzet | 6,46 x | 4,93 x | 2,86 x | 2,77 x | 1,99 x | 1,79 x | 2,14 x | 2 x |
| Bedrijfswaarde/EBITDA | 15 x | 26,9 x | 25,7 x | 34,3 x | 21,4 x | 11,6 x | 12,8 x | 11 x |
| Bedrijfswaarde/FCF | 21,6 x | 56,3 x | 130 x | -141 x | - | 38 x | 28,7 x | 16,7 x |
| FCF Yield | 4,62% | 1,78% | 0,77% | -0,71% | - | 2,63% | 3,48% | 6% |
| Price to Book | - | - | 1,8 x | - | - | - | - | - |
| Aantal aandelen (in duizenden) | 14.269 | 14.215 | 14.437 | 14.610 | 14.641 | 14.662 | - | - |
| Referentieprijs 2 | 51,85 | 45,26 | 35,83 | 29,60 | 22,66 | 26,49 | 26,49 | 26,49 |
| Datum van publicatie | 20/02/20 | 4/03/21 | 8/03/22 | 6/03/23 | 13/03/24 | - | - | - |
1USD in Miljoen2USD
Geschatte gegevens
Evolutie van de resultatenrekening (Jaargegevens)
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 114,6 | 130,5 | 147,8 | 156,2 | 166,7 | 170,3 | 181,8 | 193,9 |
| EBITDA 1 | 49,18 | 23,94 | 16,43 | 12,6 | 15,52 | 26,21 | 30,34 | 35,27 |
| Bedrijfsresultaat (EBIT) 1 | 37,11 | -28,32 | 2,615 | -19,4 | -87,64 | -8,248 | 7,594 | 1,531 |
| Operationele Marge | 32,38% | -21,71% | 1,77% | -12,42% | -52,58% | -4,84% | 4,18% | 0,79% |
| Resultaat voor belastingen (EBT) 1 | 36,12 | -28,62 | 2,427 | -18,75 | -85,33 | -3,415 | 7,78 | 6,166 |
| Nettowinst (verlies) 1 | 27,19 | -23,98 | 4,134 | -14,86 | -82,67 | -2,211 | 6,064 | 5,596 |
| Nettomarge | 23,73% | -18,38% | 2,8% | -9,51% | -49,6% | -1,3% | 3,34% | 2,89% |
| WPA 2 | 1,890 | -1,690 | 0,2800 | -1,020 | -5,640 | -0,1533 | 0,4133 | 0,3750 |
| Free Cash Flow 1 | 34,18 | 11,44 | 3,254 | -3,077 | - | 8,019 | 13,52 | 23,29 |
| FCF-marge | 29,82% | 8,77% | 2,2% | -1,97% | - | 4,71% | 7,44% | 12,01% |
| Kasstroomconversie (ebitda) | 69,49% | 47,78% | 19,8% | - | - | 30,59% | 44,57% | 66,04% |
| Kasstroomconversie (nettowinst) | 125,69% | - | 78,71% | - | - | - | 222,98% | 416,25% |
| Dividend per aandeel | - | - | - | - | - | - | - | - |
| Datum van publicatie | 20/02/20 | 4/03/21 | 8/03/22 | 6/03/23 | 13/03/24 | - | - | - |
1USD in Miljoen2USD
Geschatte gegevens
Evolutie van de resultatenrekening (Kwartaalgegevens)
| Fiscaal tijdperk: december | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 39,54 | 35,82 | 36,69 | 39,66 | 40,26 | 39,62 | 37,92 | 44,3 | 41,46 | 42,97 | 39,14 | 43,78 | 42,73 | 44,62 | 41,27 |
| EBITDA 1 | 5,747 | -0,199 | 2,608 | 4,42 | 4,05 | 1,375 | -1,204 | 6,272 | 4,65 | 5,798 | 4,442 | 7,945 | 7,068 | 6,758 | 6,092 |
| Bedrijfsresultaat (EBIT) 1 | 1,3 | -9,123 | -3,554 | -3,381 | -5,798 | -6,667 | -12,55 | -3,631 | -7,674 | -63,78 | -5,635 | -0,53 | -1,422 | -0,6615 | -0,618 |
| Operationele Marge | 3,29% | -25,47% | -9,69% | -8,53% | -14,4% | -16,83% | -33,1% | -8,2% | -18,51% | -148,43% | -14,4% | -1,21% | -3,33% | -1,48% | -1,5% |
| Resultaat voor belastingen (EBT) 1 | 1,252 | -9,17 | -3,708 | -3,285 | -5,362 | -6,391 | -12,01 | -3,07 | -7,039 | -63,2 | -3,64 | 0,7633 | -0,3893 | -0,1493 | -0,187 |
| Nettowinst (verlies) 1 | 0,558 | -5,793 | -2,933 | -2,843 | -4,175 | -4,908 | -10,35 | -2,741 | -6,576 | -63 | -2,708 | 0,7917 | -0,1963 | -0,099 | -0,1657 |
| Nettomarge | 1,41% | -16,17% | -7,99% | -7,17% | -10,37% | -12,39% | -27,29% | -6,19% | -15,86% | -146,61% | -6,92% | 1,81% | -0,46% | -0,22% | -0,4% |
| WPA 2 | 0,0400 | -0,4000 | -0,2000 | -0,2000 | -0,2900 | -0,3400 | -0,7100 | -0,1900 | -0,4500 | -4,300 | -0,1867 | 0,0567 | -0,0133 | -0,006670 | -0,0100 |
| Dividend per aandeel | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Datum van publicatie | 4/11/21 | 8/03/22 | 5/05/22 | 3/08/22 | 8/11/22 | 6/03/23 | 9/05/23 | 8/08/23 | 2/11/23 | 13/03/24 | - | - | - | - | - |
1USD in Miljoen2USD
Geschatte gegevens
Balans
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Nettoschuldpositie 1 | - | - | - | - | - | - | - | - |
| Nettokaspositie 1 | - | - | 94,4 | - | - | 84 | - | - |
| Hefboom (schuld/ebitda) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 34,2 | 11,4 | 3,25 | -3,08 | - | 8,02 | 13,5 | 23,3 |
| ROE (netto-inkomsten/eigen vermogen) | 10,7% | -8,55% | 1,48% | -5,19% | - | -3,2% | 5,5% | - |
| ROA (netto-inkomsten/totale activa) | 9,66% | -6,89% | 1,16% | -4,27% | - | -2,5% | 4,4% | - |
| Totale activa 1 | 281,5 | 348,2 | 356,6 | 348,3 | - | 88,45 | 137,8 | - |
| Nettoactief per aandeel | - | - | 19,90 | - | - | - | - | - |
| Cashflow per aandeel | - | - | - | - | - | - | - | - |
| Capex 1 | 2,83 | 1,63 | 5,14 | 7,49 | - | 10,8 | 9,75 | 8 |
| Capex/omzet | 2,47% | 1,25% | 3,48% | 4,79% | - | 6,31% | 5,36% | 4,13% |
| Datum van publicatie | 20/02/20 | 4/03/21 | 8/03/22 | 6/03/23 | 13/03/24 | - | - | - |
1USD in Miljoen
Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Historische marktkapitalisatie/EBITDA
Trading rating
Beleggingsrating
ESG Refinitiv
C
Verkoop
Koop
Gemiddeld advies
Accumuleren
Aantal analisten
3
Laatste slotkoers
26,49
USD
Gemiddelde koersdoel
30,33
USD
Spread / Gemiddelde doel
+14,51%
Herzieningen van WPA
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| +16,90% | 388 mln. | |
| -3,93% | 86,16 mld. | |
| +2,76% | 40,17 mld. | |
| -16,48% | 31,47 mld. | |
| +53,93% | 25,24 mld. | |
| -13,58% | 15,82 mld. | |
| -9,12% | 11,96 mld. | |
| -42,56% | 11,61 mld. | |
| +4,87% | 8,84 mld. | |
| -2,11% | 7,93 mld. |
- Beurs
- Aandelen
- Koers ANIK
- Financiën Anika Therapeutics, Inc.
